The affron Mood Trial: What Saffron Did for Healthy Adults With Low Mood

The affron Mood Trial: What Saffron Did for Healthy Adults With Low Mood

Most mood research recruits people who are already clinically depressed. That makes the affron saffron study unusual, and useful. It tested a standardized saffron extract on healthy adults who simply felt low, the kind of person who is functioning fine but running on a flat battery.

The headline finding was a large, measurable drop in negative mood after four weeks. Not a vague "wellness" effect. A real number on a validated psychological scale.

Here is what the trial actually did, what it found, and where the limits are.

Key Takeaways

• The affron mood trial (Kell et al., 2017) tested a saffron extract on healthy adults with self-reported low mood, not a clinical population.
• The effective dose was 28 mg per day. A lower 22 mg dose did not separate from placebo.
• On the POMS Total Mood Disturbance scale, the 28 mg group beat placebo with a large effect size (d = -1.10).
• The study ran four weeks, double-blind and placebo-controlled, which is a strong design for a supplement trial.

What the affron Saffron Study Actually Tested

The trial put a branded saffron extract up against placebo in people who were generally well but reporting low mood. Published in Complementary Therapies in Medicine, the affron paper by Kell and colleagues used a double-blind, parallel, randomized, placebo-controlled design.

Participants took the extract daily for four weeks. The researchers compared two doses, 22 mg and 28 mg per day, against a dummy pill.

The reason this matters: dose comparison is rare in supplement studies. It lets you see whether the active compound is doing the work, or whether you are watching a placebo response dressed up in a lab coat.

Saffron itself is the dried stigma of Crocus sativus. The active compounds of interest are crocins and safranal, which is why a standardized extract matters. Two saffron products are not equal unless the actives are measured and matched.

The Results: Saffron 28mg vs Placebo

The 28 mg dose worked. The 22 mg dose mostly did not. That single line is the practical takeaway of the whole saffron 28mg question.

After four weeks, the higher-dose group showed a clear improvement in mood versus placebo. The effect held up on more than one measurement tool.

The POMS Finding

The primary mood outcome came from the saffron POMS data, using the Profile of Mood States questionnaire. POMS scores six mood dimensions and rolls them into a single Total Mood Disturbance score.

On that total score, the analysis reported a marked difference between the 28 mg group and placebo (p < 0.001) with an effect size of d = -1.10. In behavioral research, an effect size above 0.8 is considered large, so this was not a marginal result.

The same group also reported increased vigor on POMS. So the benefit was not only "less bad mood" but also more felt energy.

The DASS-21 Finding

The researchers backed up POMS with a second instrument, the DASS-21, which measures depression, anxiety, and stress symptoms. The 28 mg group showed a decrease in stress and depression scores compared to placebo.

When two separate validated questionnaires point the same direction, the finding gets more credible. One scale can fluke. Two agreeing is harder to wave away.

Why "Saffron in Healthy Adults" Is the Interesting Part

Plenty of trials show saffron helping people with diagnosed depression. The value of saffron healthy adults research is different. It asks whether a botanical can support mood in people who are not sick, just below their baseline.

That population is large and mostly ignored by clinical literature. You are not depressed. You are flat, tired, a little frayed. The affron trial is one of the few that measured exactly that group.

This is also where the work of researchers like Adrian Lopresti becomes relevant. The broader body of lopresti saffron research has examined saffron across mood, sleep, and stress outcomes in several populations, building a case that the extract has effects beyond the clinically depressed.

A practical caution holds here. "Supports mood" is not the same as "treats depression." The affron data describes support in healthy people, not a substitute for care when someone is genuinely unwell.

How the affron Trial Stacks Up Against Other Mood Approaches

No single ingredient owns mood. Here is an honest comparison of how saffron sits next to other common, evidence-backed options people reach for.

The takeaway is that saffron plays a slow, cumulative role. It is not an acute lever you pull before a meeting. That distinction matters when you decide what problem you are actually solving.

The Limits Worth Knowing

This was a four-week study. It tells you little about what happens at six months or a year.

The sample was healthy adults with mild low mood, so the result does not transfer to clinical depression without separate trials. And affron is a branded, standardized extract, which means generic saffron at a random dose may not reproduce the effect.

Funding is also fair to flag. Industry-linked supplement trials are common and not automatically suspect, but independent replication always strengthens a claim. Saffron has earned a reasonable amount of that replication, which is more than most botanicals can say.

Conclusion

The affron trial answered a narrow, useful question. In healthy adults with low mood, a standardized saffron extract at 28 mg per day lowered negative mood and raised vigor over four weeks, with a large effect size on the POMS and supporting evidence on the DASS-21.

The dose-dependence is the most quietly important detail. The fact that 28 mg worked and 22 mg did not suggests a real pharmacological effect rather than wishful thinking. Saffron is not a cure for anything, and it acts slowly. But as a daily, evidence-supported lever for everyday mood, it has earned its place in the conversation.

Frequently Asked Questions

What is the affron saffron study?

It is a 2017 randomized, double-blind, placebo-controlled trial by Kell and colleagues, published in Complementary Therapies in Medicine. It tested a standardized saffron extract (affron) on healthy adults reporting low mood over four weeks, comparing 22 mg and 28 mg daily doses against placebo. The 28 mg dose produced a marked improvement in mood.

What dose of saffron did the trial find effective?

The trial found 28 mg per day effective. The lower 22 mg dose did not separate meaningfully from placebo, which points to a dose-dependent effect. This is why many saffron supplements aiming to match the research target the 28 mg standardized dose specifically.

What is the POMS scale used in the study?

POMS stands for Profile of Mood States, a validated questionnaire that scores six mood dimensions and combines them into a Total Mood Disturbance score. In the affron trial, the 28 mg group showed a marked improvement on this total score versus placebo (p < 0.001, effect size d = -1.10), which counts as a large effect.

Does saffron work for people who are not depressed?

This study suggests it can support mood in healthy adults with mild low mood, which is exactly who it recruited. It does not show saffron treats clinical depression, and it is not a substitute for professional care. The finding is about everyday mood support, not medical treatment.

How long until saffron affects mood?

The affron trial measured results over four weeks of daily use. Saffron appears to work cumulatively rather than acutely, so it is a daily-habit ingredient, not something you take for an immediate lift before a stressful event.

Who is Adrian Lopresti and why does his name come up?

Adrian Lopresti is a researcher who has published several studies on saffron and mood, sleep, and stress across different populations. The broader lopresti saffron literature helps build the case that standardized saffron extracts have measurable effects beyond clinically depressed groups.

Is the affron saffron study reliable?

Its design is strong for a supplement trial: randomized, double-blind, placebo-controlled, with a dose comparison. The main limits are the short four-week window, the healthy-but-low-mood sample, and industry links common to branded-ingredient research. Independent replication of saffron's mood effects exists, which adds confidence.

Where the Evidence Meets Everyday Performance

Saffron sits in the slow lane of mood support, a daily ingredient that builds over weeks. That makes it a useful contrast to the faster side of cognitive performance, where the goal is sharp, calm focus in the next ten minutes rather than the next month.

Roon lives on that faster side. It is a sublingual cognitive performance pouch built on four ingredients: 80 mg caffeine, 60 mg L-theanine, 25 mg methylliberine (Dynamine), and 5 mg theacrine (TeaCrine), designed for a 5 to 10 minute onset and 6 to 8 hours of focus with no jitters, no crash, and no tolerance buildup. It is built for acute focus, not for long-term mood support, and it is not a replacement for the daily habits that move mood over time.

If you want the deeper science on botanicals like saffron, that is what our research breakdowns are for. Start with Roon, then read the saffron deep dive as the companion piece on what the evidence shows in healthy people.

Written by Roon Team